• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Correction to “Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials”

by | Jun 11, 2024 | Publications

Am J Hematol. 2024 Jun 11. doi: 10.1002/ajh.27380. Online ahead of print. NO ABSTRACT PMID:38860647 | DOI:10.1002/ajh.27380

Clinical consensus on treatments for transplant-ineligible newly diagnosed multiple myeloma: double-blinded Delphi panel

by | Jun 11, 2024 | Publications

Future Oncol. 2024 May 20:1-12. doi: 10.1080/14796694.2024.2342228. Online ahead of print. ABSTRACT Aim: Obtain clinical consensus on factors impacting first-line prescribing for transplant-ineligible (TIE) patients with newly diagnosed multiple myeloma (NDMM)....

Skeletal-Related Events in Patients With Multiple Myeloma: A Comprehensive Retrospective Cohort Study

by | Jun 11, 2024 | Publications

J Korean Med Sci. 2024 Jun 10;39(22):e175. doi: 10.3346/jkms.2024.39.e175. ABSTRACT BACKGROUND: Multiple myeloma (MM) patients are at risk of skeletal-related events (SREs) like spinal cord compression, pathologic fractures, bone surgery, and radiation to bone....

Multiple Myeloma with Concurrent Pericardial Effusion

by | Jun 11, 2024 | Publications

Kans J Med. 2024 Jun 4;17:64-66. doi: 10.17161/kjm.vol17.21630. eCollection 2024. NO ABSTRACT PMID:38859988 | PMC:PMC11164422 | DOI:10.17161/kjm.vol17.21630

Remineralization Rate of Lytic Lesions of the Spine in Multiple Myeloma Patients Undergoing Radiation Therapy

by | Jun 10, 2024 | Publications

Global Spine J. 2024 Jun 10:21925682241260651. doi: 10.1177/21925682241260651. Online ahead of print. ABSTRACT STUDY DESIGN: Retrospective cohort study. OBJECTIVE: In general, Multiple Myeloma (MM) patients are treated with systemic therapy including chemotherapy....

Ixazomib plus daratumumab and dexamethasone: Final analysis of a phase 2 study among patients with relapsed/refractory multiple myeloma

by | Jun 10, 2024 | Publications

Am J Hematol. 2024 Jun 10. doi: 10.1002/ajh.27382. Online ahead of print. ABSTRACT Novel therapies have improved outcomes for multiple myeloma (MM) patients, but most ultimately relapse, making treatment decisions for relapsed/refractory MM (RRMM) patients...
« Older Entries
Next Entries »

Recent Content

  • (no title)
  • Efficacy of novel therapies for refractory and relapsed multiple myeloma in China: A scoping systematic review
  • Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma
  • Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma
  • (no title)
  • Correction: Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement
  • Sex-specific dysregulation of exosomal non-coding RNAs drives multiple myeloma progression
  • (no title)
  • (no title)
  • Multi-cohort high-dimensional proteomics reveals early risk markers for lymphoid cancer subtypes
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT